ArticleThe Journal of infectious diseases2026
Peak Nasal SARS-CoV-2 and Influenza Viral Loads Relative to Symptom Onset, 2022-2025: Impact of Vaccination and Implications for Multiplexed Testing.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
backgroundWe previously reported that nasal SARS-CoV-2 viral loads (VLs) peaked around the fourth day of symptoms in highly immune adults sampled April 2022 to April 2023, while influenza A VLs peaked soon after symptom onset. We hypothesized that SARS-CoV-2 kinetics may have changed due to reduced COVID-19 incidence and altered vaccination patterns. Understanding how viral kinetics evolve over time is essential to inform testing strategies.
methodsParticipants with symptomatic upper respiratory infection were recruited at testing centers in Georgia 14 April 2023 to 11 April 2025. Participants reported date of symptom onset and vaccination history. A nasal swab was tested on the Xpert Xpress CoV-2/Flu/RSV-Plus assay and cycle threshold (Ct) values recorded.
results552 adults (aged ≥16 years) and 60 children (aged <16 years) were SARS-CoV-2 positive; lowest median Ct values (highest VL) were observed on the second symptomatic day. Adults vaccinated within 12 months (n = 106) had peak VL on the third day, and those vaccinated ≥12 months prior (n = 334), on the second. In influenza A-positive adults (n = 181) and children (n = 147), median VL peaked on the first symptomatic day, vs the fourth day in 157 influenza B-positive participants.
conclusionsIn 2023-2025, median SARS-CoV-2 VL peaked earlier relative to symptom onset compared to a highly immune 2022-2023 cohort. More recent vaccination correlated with delayed peak VL, suggesting that more robust immunity correlates with earlier symptom onset relative to peak. Median influenza A VLs were highest at symptom onset, vs 4 days into symptoms for influenza B. These findings can inform use of multiplexed antigen tests amidst changing immunity and viral circulation patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.